FAS and lung carcinoma: Our data are rather in line with a study on lung adenocarcinomas, which showed that targeting CD95, c-FLIP, or NF-κB signaling by RNA interference sensitized lung cancer cells towards EGFR tyrosine kinase inhibitors60.